Merck Launches Phase 3 Trial Combining Calderasib With Keytruda QLEX for Lung Cancer

Merck announced this week that it has moved forward with a Phase 3 clinical trial designed to test whether calderasib, a newer drug candidate, works better when paired with Keytruda QLEX—the company's established immunotherapy—in treating a specific form of advanced lung cancer. The trial focuses on patients whose tumors carry a KRAS G12C mutation, a genetic marker that identifies a distinct subset of nonsquamous non-small cell lung cancer cases.

The decision to combine these two drugs represents a deliberate strategy in Merck's oncology pipeline. Keytruda QLEX is already an approved treatment that helps the immune system recognize and attack cancer cells. Calderasib is a newer agent designed to target the KRAS protein, which is frequently mutated in lung cancers and has historically been difficult to treat. By testing them together, Merck is betting that the combination will prove more effective than either drug alone.

Non-small cell lung cancer accounts for the majority of all lung cancer diagnoses. Within that category, the nonsquamous subtype—which excludes squamous cell carcinomas—represents a large patient population. The KRAS G12C mutation, once considered untargetable, has become an increasingly important focus for drug developers over the past several years as new compounds have shown promise in clinical settings. Patients with this specific mutation have limited treatment options, making this trial potentially significant for a meaningful number of people.

The Phase 3 designation means the trial has moved beyond early safety testing and smaller proof-of-concept studies. Phase 3 trials are typically larger, involve multiple clinical sites, and are designed to confirm that a treatment works as intended and to monitor side effects in a broader patient population. Success at this stage is often the final hurdle before a company can seek regulatory approval from agencies like the FDA.

For Merck, advancing calderasib into Phase 3 testing represents progress in a competitive oncology landscape. Lung cancer treatment has become increasingly crowded, with multiple companies developing immunotherapies and targeted agents. The high commercial value of effective cancer treatments means that companies invest heavily in combinations that might offer patients better outcomes than existing options. If this trial demonstrates that the pairing of calderasib with Keytruda QLEX improves survival or response rates compared to current standards, it could become an important addition to Merck's portfolio and potentially reshape treatment approaches for this patient population.

The trial's success is far from guaranteed. Many promising combinations fail to meet their primary endpoints in Phase 3 testing, and even when drugs work in earlier trials, larger studies sometimes reveal unexpected toxicities or modest benefits that don't justify approval. But for patients with KRAS G12C-mutant advanced lung cancer—a diagnosis that remains serious despite recent therapeutic advances—the initiation of this trial signals that researchers continue to search for better ways to extend survival and improve quality of life.